FDA
- Status: approved
Tongren-Dahuoluo Bolus (Tongren-Dahuoluo Bolus) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.